A comparison of the clinical and genetic features of Amyotrophic Lateral Sclerosis across Latin American and European populations

Disclosure:
Dr. Hardiman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Wave Life Sciences, Cytokinetics, Treeway. Dr. Hardiman has received personal compensation in an editorial capacity for Taylor and Francis .

Disclosure:
Dr. Warrior has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with John Redmond Esq.

Movement Disorders ePoster Session

Start Time

Pub.

Title

Presenter

11:30 AM

003

Disruption of spermatogenesis and infertility in Ataxia with Oculomotor Apraxia Type 2 (AOA2)

Disclosure:
Dr. Fogel has nothing to disclose.

Migraine II

Start Time

Pub.

Title

Presenter

11:30 AM

003

Rates of Associated Health Conditions in Those with Migraine vs. Non-migraine Controls: Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study

Disclosure:
Dr. Buse has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with Dawn Buse PhD has received honoraria from Allergan Amgen Biohaven Lilly Teva and Promius. Dr. Buse has received personal compensation in an editorial capacity for editorial board of Current Pain and Headache Reports. Dr. Buse has received research support from Amgen.

Check Point Inhibitors and Paraneoplastic Neurological Disorders

Start Time

Pub.

Title

Presenter

11:30 AM

003

Immune checkpoint inhibitor induced anti-GAD limbic encephalitis

Disclosure:
Dr. Chung has nothing to disclose.

Unusual Stroke Etiologies, Presentations and Treatments

Start Time

Pub.

Title

Presenter

11:30 AM

003

A Rare Case of Air Embolus During Administration of tPA for Acute Ischemic Stroke

Progression of Symptoms in relation to the Site of Onset in Amyotrophic Lateral Sclerosis: new Evidence supporting the Prion-like Hypothesis

Disclosure:
Dr. Chio has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Cytokinetics, Roche. Dr. Chio has received research support from Italfarmaco.

Dystonia and Botulinum Toxin Therapy

Start Time

Pub.

Title

Presenter

11:30 AM

004

The Dystonia Coalition Natural History Project: Nine Years of Progress

Hyperglycemic Induced Chorea-Ballismus Responsive to Valbenazine: a Video Case Report and Review of the Literature.

Disclosure:
Dr. Saunders has nothing to disclose.

Migraine II

Start Time

Pub.

Title

Presenter

11:30 AM

008

Methylation Analyses of Stress-Modified Genes in Migraine

Disclosure:
Dr. Oterino Duran has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Almirall, Merck Serono, TEVA, Sanofi Genzyme, Allergan, MSD and Novartis. Dr. Oterino Duran has received research support from Sanofi Genzyme, Novartis.

Healthcare Expenditure in Migraine Compared to Other Leading Causes of Disability: Adequate or Not?

Disclosure:
Dr. Schaetz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis Pharma AG, Switzerland.

MS Therapeutics: MOA and Safety

Start Time

Pub.

Title

Presenter

11:30 AM

009

Longitudinal stability of anti–JC virus (JCV) antibody index over 2 years in multiple sclerosis (MS) patients treated with natalizumab in the ASCEND study

Disclosure:
Dr Mason is an employee of Biogen and receives personal compensation for employment. Dr Mason is an employee of Biogen and has received stock options from Biogen. Dr Mason is an employee and held stock in Biogen.

Unusual Stroke Etiologies, Presentations and Treatments

Start Time

Pub.

Title

Presenter

11:30 AM

009

CNS Manifestations of Hemophagocytic Lymphohistiocytosis (HLH)

Disclosure:
Dr. Edwards has nothing to disclose.

Motor Neuron Disease

Start Time

Pub.

Title

Presenter

11:30 AM

009

Monitoring and promoting effectiveness and adherence to non-invasive ventilation in motor neurone disease using EncoreAnywhere telemonitoring: a pilot and feasibility, randomised controlled trial.

Disclosure:
Dr. James has nothing to disclose.

Epilepsy: EEG and Neurophysiology

Start Time

Pub.

Title

Presenter

11:30 AM

009

Validation of a dry-electrode EEG recording system: Results of a multi-reader blinded comparison to standard EEG

Disclosure:
Dr. Zarroli has nothing to disclose.

Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy

Start Time

Pub.

Title

Presenter

11:30 AM

009

An increase in the prevalence of Multiple Sclerosis has moved Kuwait to a high-risk zone

Disclosure:
Dr. Alroughani has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer, Biogen, Biologix, Merck, Novartis, Roche and Sanofi. Dr. Alroughani has received research support from Biogen, Merck, Novartis, Roche and Sanofi.

Disclosure:
Dr. Mazurkiewicz Beldzin has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Biomarin.

Epilepsy: EEG and Neurophysiology

Start Time

Pub.

Title

Presenter

11:30 AM

012

Diagnostic Utility of Continuous sEMG Monitoring in a Home Setting - Real-world use of the SPEAC® System

Disclosure:
Dr. Whitmire has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Brain Sentinel.

Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy

Start Time

Pub.

Title

Presenter

11:30 AM

012

Vision loss in Parkinson’s disease: prevalence and association with outcomes among Medicare beneficiaries

Disclosure:
Dr. Hamedani has nothing to disclose.

Dystonia and Botulinum Toxin Therapy

Start Time

Pub.

Title

Presenter

11:30 AM

012

Immunogenicity of DaxibotulinumtoxinA for Injection in Adults with Cervical Dystonia from a Phase 2 Dose-Escalation Multicenter Study

Disclosure:
Dr. Brashear has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ipsen and Revance. Dr. Brashear has received research support from Wake Forest.

Intranasal Glulisine in Down Syndrome: A Pilot Safety and Tolerability Trial

Disclosure:
Dr. Rosenbloom has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Paul Weiss. Dr. Rosenbloom has received research support from Merck Foundation.

Migraine II

Start Time

Pub.

Title

Presenter

11:30 AM

015

Effect of Galcanezumab on Severity of Headache and Associated Symptoms of Migraine in Phase 3 Trials in Patients with Episodic or Chronic Migraine

Disclosure:
Dr. Day has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Eli Lilly and Company.

MS Therapeutics: MOA and Safety

Start Time

Pub.

Title

Presenter

11:30 AM

015

Evaluating the Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Infusion Related Reactions in Relapsing Forms of Multiple Sclerosis

Disclosure:
Dr. Alvarez has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with consulting fees from Actelion, Biogen, Celgene, EMD Serono, Genentech, Genzyme, Novartis, and TG Therapeutics. Dr. Alvarez has received research support from Biogen, Genentech, Novartis, TG Therapeutics, and Rocky Mountain MS Center.

Unusual Stroke Etiologies, Presentations and Treatments

Start Time

Pub.

Title

Presenter

11:30 AM

015

Lacunar Strokes in Cryptococcal Meningitis: Clinical and Radiographic Features in a U.S. Cohort

Disclosure:
Dr. Vela-Duarte has nothing to disclose.

Motor Neuron Disease

Start Time

Pub.

Title

Presenter

11:30 AM

015

Nusinersen in Adults with Spinal Muscular Atrophy, A Single Center Experience

Disclosure:
Dr. Moshe-Lilie has nothing to disclose.

Epilepsy: EEG and Neurophysiology

Start Time

Pub.

Title

Presenter

11:30 AM

015

Ictal urinary urgency localized by Stereo-electroencephalogram.

Disclosure:
Dr. Murray-Frank has nothing to disclose.

Neuroepidemiology: Stroke, Critical Care, Headache and Global Health

Start Time

Pub.

Title

Presenter

11:30 AM

015

Cognitive decline after a mild or moderate stroke and TIA: evidence from the SWIFT Trial

Determinants of Mortality Among Hospitalized Patients with Amyotrophic Lateral Sclerosis – Results from the 2016 National Inpatient Sample

Disclosure:
Dr. L'Italien has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biohaven Pharmaceuticals. Dr. L'Italien holds stock and/or stock options in Biohaven Pharmaceuticals which sponsored research in which Dr. L'Italien was involved as an investigator. Dr. L'Italien holds stock and/or stock options in Biohaven Pharmaceuticals. Dr. L'Italien has received research support from Biohaven Pharmaceuticals.

Epilepsy: EEG and Neurophysiology

Start Time

Pub.

Title

Presenter

11:30 AM

017

Wearable Sensors for the Detection of Convulsive Seizures

Disclosure:
Dr. McGinn has nothing to disclose.

Neuroepidemiology: Stroke, Critical Care, Headache and Global Health

Start Time

Pub.

Title

Presenter

11:30 AM

017

Disparities, Predictors and Trends of Left Atrial Appendage Closure Among Hospitalized Patients with Atrial Fibrillation in the United States

Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene?Related Peptide Receptor

Disclosure:
Dr. Moore has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck & Co., Inc. Dr. Moore holds stock and/or stock options in Merck & Co., Inc which sponsored research in which Dr. Moore was involved as an investigator.

Aging and Dementia: Neuropsychology and Clinical Studies II

Start Time

Pub.

Title

Presenter

11:30 AM

021

Real World Treatment of Parkinson’s Disease Dementia (PDD) in the United States (U.S.)

Disclosure:
Dr. Schroeder has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Schroeder holds stock and/or stock options in Eli Lilly and Company which sponsored research in which Dr. Schroeder was involved as an investigator. .

MS Therapeutics: MOA and Safety

Start Time

Pub.

Title

Presenter

11:30 AM

021

Risk factors for Development of Lymphopenia in Dimethyl Fumarate-treated Patients with Multiple Sclerosis

Response to Lasmiditan for Acute Treatment of Migraine Based on Prior Response to Triptan Therapy

Disclosure:
Dr. Knievel has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Consulting for Amgen, Lilly, Allergan, Biohaven. Speaking Amgen and Allergan.. Dr. Knievel has received research support from Allergan; Alder.

Adherence to Riluzole Therapy Improves Time to and Frequency of All Cause Hospitalization in ALS Patients: A Claims-Based Longitudinal Comparative Effectiveness Analysis.

Disclosure:
Dr. L'Italien has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biohaven Pharmaceuticals. Dr. L'Italien holds stock and/or stock options in Biohaven Pharmaceuticals which sponsored research in which Dr. L'Italien was involved as an investigator. Dr. L'Italien holds stock and/or stock options in Biohaven Pharmaceuticals. Dr. L'Italien has received research support from Biohaven Pharmaceuticals.

Kufor-Rakeb Syndrome with Prominent Dystonia and New Mutations in ATP13A2 Gene in Two Siblings

Disclosure:
Dr. Yamasaki has nothing to disclose.

Neurovirology

Start Time

Pub.

Title

Presenter

11:30 AM

023

A Quality Improvement Project Studying the Integration of a Proposed Diagnostic Algorithm on Inpatient Encephalitis into the Electronic Medical Record and its Impact on Length of Hospital Stay

Disclosure:
Dr. Kaplan has nothing to disclose.

Migraine II

Start Time

Pub.

Title

Presenter

11:30 AM

023

Impact of OnabotulinumtoxinA on Quality of Life, Health Resource Utilization, and Work Productivity in People With Chronic Migraine: Interim Results From a Prospective, Observational Study (PREDICT)

Disclosure:
Dr. Boudreau has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Amgen, Lilly, and Teva. Dr. Boudreau has received research support from Allergan, Amgen, Lilly, and Teva.

Disclosure:
Dr. Chan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer, Biogen, Genzyme, Merck, Novartis, Roche, Teva, Swiss National Fonds, Genzyme and UCB, Clinical and translational neuroscience and the Journal of International medical research. Dr. Chan has received research support from Bayer, Biogen, Genzyme, Merck, Novartis, Roche, Teva, Swiss National Fonds, Genzyme and UCB, Clinical and translational neuroscience and the Journal of International medical research.

Unusual Stroke Etiologies, Presentations and Treatments

Start Time

Pub.

Title

Presenter

11:30 AM

023

Simultaneous Epidural and Intramedullary Hemorrhage: A Case Report.

Disclosure:
Dr. Shah has nothing to disclose.

Motor Neuron Disease

Start Time

Pub.

Title

Presenter

11:30 AM

023

Diffusion Tension Imaging as the Biomarker for Amyotrophic Lateral Sclerosis

Disclosure:
Dr. Baek has nothing to disclose.

Epilepsy: EEG and Neurophysiology

Start Time

Pub.

Title

Presenter

11:30 AM

023

Normalized transfer entropy used as an informational transfer measure of ictal pathophysiology in patients undergoing stereo-EEG for epilepsy surgery

Disclosure:
Dr. Lee has received research support from America Epilepsy Society.

Neuroepidemiology: Stroke, Critical Care, Headache and Global Health

Start Time

Pub.

Title

Presenter

11:30 AM

023

Acute neurological complications after adult single and double lung transplant

Disclosure:
Dr. Rauf has nothing to disclose.

Dystonia and Botulinum Toxin Therapy

Start Time

Pub.

Title

Presenter

11:30 AM

023

The Trend in Botulinum Toxin Injection among Medicare Neurology Providers in the United States from 2012 to 2016

Disclosure:
Dr. Miri has nothing to disclose.

Neurovirology

Start Time

Pub.

Title

Presenter

11:30 AM

024

A simple bioinformatics approach to disentangle the etiology and prognosis of CNS infections

Disclosure:
Dr. Tan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis, Merck, UCB, Sanofi Genzyme and Eisai.

Migraine II

Start Time

Pub.

Title

Presenter

11:30 AM

024

Eptinezumab Increases Days Free from Canonical Migraine-Associated Symptoms Within 1 Month of Treatment in Patients with Chronic Migraine

Disclosure:
Dr. Montes has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Astellas, Biogen, Cytokinetics, Roche, and Scholar Rock. Dr. Montes has received research support from MDA and NICHD / NIH.

Association between neurological syndromes and Arbovirus in Buenos Aires - Relationship between Guillain Barre Syndrome, Encephalitis and Myelitis with Zika, Dengue and Chikungunya

Disclosure:
Dr. Kohler has nothing to disclose.

Dystonia and Botulinum Toxin Therapy

Start Time

Pub.

Title

Presenter

11:30 AM

024

RimabotulinumtoxinB (MYOBLOC) in the treatment of adult sialorrhea

Disclosure:
Dr. Ondo has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with UCBPharma, TEVA, USWorldMeds, Neurocrine, ADAMAS. Dr. Ondo has received research support from Lundbeck, Sunovian, Neuroderm.

Neurovirology

Start Time

Pub.

Title

Presenter

11:30 AM

025

Evaluation of BioFire Film Array Meningitis/ Encephalitis (ME) panel in testing of CSF specimen of patients of meningoencephalitis in Indian scenario

Disclosure:
Dr. Hauser has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Annexon, Symbiotix, Bionure and Neurona; he has also received travel reimbursement from F. Hoffmann-La Roche Ltd and Novartis for CD20-related meetings and presentation.

Unusual Stroke Etiologies, Presentations and Treatments

Start Time

Pub.

Title

Presenter

11:30 AM

025

Spinal Cord Infarction: A Diagnostic Challenge

Disclosure:
Dr. Passeri has nothing to disclose.

Motor Neuron Disease

Start Time

Pub.

Title

Presenter

11:30 AM

025

Population Based Surveillance and Survival Characteristics of Amyotrophic Lateral Sclerosis (ALS) Cases in the Atlanta Metropolitan Area, 2009 – 2011

Individualized OnabotulinumtoxinA Treatment for Upper Limb Spasticity Resulted in High Patient and Clinician Satisfaction in the ASPIRE Study

Disclosure:
Dr. Francisco has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Merz, and Ipsen. Dr. Francisco has received research support from Allergan, Merz, and Ipsen.

Neurovirology

Start Time

Pub.

Title

Presenter

11:30 AM

026

Progressive Multifocal Leukoencephalopathy in an Immunocompetent Patient: A Rare Case with Radiologic-Pathologic Correlation

Disclosure:
Dr. Grober has received royalty, license fees, or contractual rights payments from Albert Einstein College of Medicine.

MS Therapeutics: MOA and Safety

Start Time

Pub.

Title

Presenter

11:30 AM

026

Influence of Clinical and Cerebrospinal Fluid Parameters on the Effect of Therapeutic Plasma Exchange in Patients with Multiple Sclerosis

Disclosure:
Dr. Eienbröker has nothing to disclose.

Unusual Stroke Etiologies, Presentations and Treatments

Start Time

Pub.

Title

Presenter

11:30 AM

026

CADASIL in a Patient with Bilateral Internal Carotid Artery Agenesis

Disclosure:
Dr. MacDonald has nothing to disclose.

Motor Neuron Disease

Start Time

Pub.

Title

Presenter

11:30 AM

026

Factors Associated with Poor Compliance of Non-invasive Ventilator Support in Patients with ALS

Disclosure:
Dr. Kohli has nothing to disclose.

Epilepsy: General Medical Issues, PNES, and Other

Start Time

Pub.

Title

Presenter

11:30 AM

026

Prognosis and Clinical Factors to Predict Seizure Recurrence in Patients with Alcohol-Related Seizures

Disclosure:
Dr. Chun has nothing to disclose.

Neuroepidemiology: Stroke, Critical Care, Headache and Global Health

Start Time

Pub.

Title

Presenter

11:30 AM

026

The Pattern of Neurologic Disease in Tanzanian Tribal Populations

Disclosure:
Dr. Aamodt has nothing to disclose.

Dystonia and Botulinum Toxin Therapy

Start Time

Pub.

Title

Presenter

11:30 AM

026

Individualized OnabotulinumtoxinA Treatment for Lower Limb Spasticity Resulted in High Patient and Clinician Satisfaction in the ASPIRE Study

Disclosure:
Dr. Esquenazi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Ipsen, and Mertz. Dr. Esquenazi has received research support from Allergan and Ipsen.

Disclosure:
Dr. Rist has received personal compensation in an editorial capacity for Stroke - a journal of the American Heart Association.

Dystonia and Botulinum Toxin Therapy

Start Time

Pub.

Title

Presenter

11:30 AM

027

Botulinum Toxin for the treatment of muscle spasms associated with Stiff Person Syndrome

Disclosure:
Dr. Moukheiber has nothing to disclose.

Neurovirology

Start Time

Pub.

Title

Presenter

11:30 AM

028

Neuroinvasive West Nile Virus: a Case Series in Nebraska

Disclosure:
Dr. Purbaugh has nothing to disclose.

Aging and Dementia: Neuropsychology and Clinical Studies II

Start Time

Pub.

Title

Presenter

11:30 AM

028

The Role of Population Receptive Fields' Size in Understanding Complex Visual Dysfunctions: Posterior Cortical Atrophy Model

Disclosure:
Dr. De Best has nothing to disclose.

MS Therapeutics: MOA and Safety

Start Time

Pub.

Title

Presenter

11:30 AM

028

Changes in the immune cell profile in fingolimod-treated patients with relapsing multiple sclerosis: primary analysis of the FLUENT study

Disclosure:
Dr. Mao-Draayer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Accorda, Biogen, Bayer Pharmaceutical, Celgene, Teva, Genentech, Sanofi-Genzyme, Novartis, Chugai and EMD Serono. Dr. Mao-Draayer has received research support from NIH NIAID Autoimmune Center of Excellence, Sanofi-Genzyme, Novartis and Chugai.

Unusual Stroke Etiologies, Presentations and Treatments

Start Time

Pub.

Title

Presenter

11:30 AM

028

Recurrent Stroke in Giant Cell Arteritis Despite Immunotherapy

Disclosure:
Dr. Cox has nothing to disclose.

Motor Neuron Disease

Start Time

Pub.

Title

Presenter

11:30 AM

028

Facial Onset Sensory-Motor Neuronopathy: A Series of Two Cases Illustrating a Disease Spectrum

Disclosure:
Dr. Berkovich has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Avanir, Bayer, Biogen, Novartis, Questcor, Sanofi, and Teva. Dr. Berkovich has received research support from Acorda, Avanir, Bayer, Biogen, Novartis, Questcor, Sanofi, and Teva.

Disclosure:
Dr. Heiman-Patterson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Cytokinetics, Mitsubishi Tanabe, PTC Therapeutics.

Disclosure:
Dr. Conway has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Arena pharmaceuticals. Dr. Conway has received personal compensation in an editorial capacity for Neurotherapeutics. Dr. Conway has received research support from Novartis Pharmaceuticals.

Oculomeningoencephalomyeloradiculitis: A case of fulminant varicella zoster infection in the setting of systemic lupus erythematosus

Disclosure:
Dr. Perrone has nothing to disclose.

MS Therapeutics: MOA and Safety

Start Time

Pub.

Title

Presenter

11:30 AM

036

Skin Warts during Fingolimod Treatment in Patients with Multiple Sclerosis

Disclosure:
Dr. Yamout has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer, Biogen, Genpharm, Genzyme, Merck-Serono, Novartis. Dr. Yamout has received research support from Bayer, Biogen, Merck-Serono, Novartis, Pfizer.

Disclosure:
Dr. Eibling has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with TrueLearn .

MS Therapeutics: MOA and Safety

Start Time

Pub.

Title

Presenter

11:30 AM

037

Limited Effects of Interferon ß-1a in an IgG-driven Model of Multiple Sclerosis Pathology

Disclosure:
Dr. Bennett has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with MedImmune, Equillium, Chugai, Frequency Therapeutics, Clene Neuroscience. Dr. Bennett has received research support from Mallinckrodt, EMD Serono.

Unilateral Primary CNS Vasculitis in a Child Associated with Increased ICP and Treated with Maximal Medical Therapy and Decompressive Hemicraniectomy

Disclosure:
Dr. Wang has nothing to disclose.

Other Hyperkinetic Movement Disorders and Tremor

Start Time

Pub.

Title

Presenter

11:30 AM

039

Physical activity, sleep and tic severity in children

Disclosure:
Dr. Pringsheim has nothing to disclose.

Neurovirology

Start Time

Pub.

Title

Presenter

11:30 AM

040

Acute Myositis in Three Adult Men with Rapid Resolution

Disclosure:
Dr. Danielson has nothing to disclose.

MS Therapeutics: MOA and Safety

Start Time

Pub.

Title

Presenter

11:30 AM

040

Stability of JC Virus Index over Time – a Five Year Retrospective Study.

Disclosure:
Dr. Gaughan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche, Novartis, Abbvie, Biogen. Dr. Gaughan has received research support from Roche via Newman Fellowship, University College Dublin.

Disclosure:
Dr. Fadda has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi Genzyme.

Other Hyperkinetic Movement Disorders and Tremor

Start Time

Pub.

Title

Presenter

11:30 AM

042

Development of an EMG Based Tic Detector

Disclosure:
Dr. Deeb has received research support from Tools4Patients.

History of Neurology

Start Time

Pub.

Title

Presenter

11:30 AM

043

Potassium Bromide: The First Successful Treatment of Epilepsy

Disclosure:
Dr. Peng has nothing to disclose.

MS Therapeutics: MOA and Safety

Start Time

Pub.

Title

Presenter

11:30 AM

043

VERISMO: A Post-Marketing Safety Study to Determine the Incidence of All Malignancies and Breast Cancer in Patients With Multiple Sclerosis Treated With Ocrelizumab

Disclosure:
Dr. Wormser has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F. Hoffman-La Roche Ltd. Dr. Wormser has received compensation for serving on the Board of Directors of F. Hoffman-La Roche Ltd. Dr. Wormser has received research support from F. Hoffman-La Roche Ltd.

Stroke Genetics and Epidemiology

Start Time

Pub.

Title

Presenter

11:30 AM

043

Acute Stroke Management: A Plight of Nepal

Disclosure:
Dr. Chandra has nothing to disclose.

Child Neurology: Leukodystrophies

Start Time

Pub.

Title

Presenter

11:30 AM

043

Natural History of Neurological and Neuroimaging Progression in Childhood Cerebral X-Linked Adrenoleukodystrophy (CCALD).

Disclosure:
Dr. Almuqbil has nothing to disclose.

Other Hyperkinetic Movement Disorders and Tremor

Start Time

Pub.

Title

Presenter

11:30 AM

043

Prescriptions for Alpha Agonists and Antipsychotics in Children and Youth with Tic Disorders: A National Pharmacoepidemiologic Study

Cross-analysis of Interferon Signature in a cohort of Aicardi-Goutières Syndrome subjects

Disclosure:
Dr. Gavazzi has nothing to disclose.

Other Hyperkinetic Movement Disorders and Tremor

Start Time

Pub.

Title

Presenter

11:30 AM

046

Smartphone Accelometry in Diagnosing Orthostatic Tremor

Disclosure:
Dr. Calvo has nothing to disclose.

History of Neurology

Start Time

Pub.

Title

Presenter

11:30 AM

047

Conceptualizing Consciousness as Arousal+Awareness – Historical Parallels from Indian Philosophy

Disclosure:
Dr. Venkatraman has nothing to disclose.

MS Therapeutics: MOA and Safety

Start Time

Pub.

Title

Presenter

11:30 AM

047

Efficacy and Safety of Teriflunomide in Patients of Differing Ages: Analysis of Pooled Clinical Trials

Disclosure:
Dr. Oh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, EMD Serono, Genzyme, Novartis, Roche. Dr. Oh has received research support from Biogen Idec, Genzyme, MS Society of Canada, Teva.

Stroke Genetics and Epidemiology

Start Time

Pub.

Title

Presenter

11:30 AM

047

Serious Misdiagnosis-Related Harms Due to Missed Vascular Events in the United States—Incidence, Settings, and Causes

Disclosure:
Dr. Saber Tehrani has nothing to disclose.

Child Neurology: Leukodystrophies

Start Time

Pub.

Title

Presenter

11:30 AM

047

Consensus Guidelines: MRI Surveillance of Children with Presymptomatic Adrenoleukodystrophy

Disclosure:
Dr. Turk has nothing to disclose.

Other Hyperkinetic Movement Disorders and Tremor

Start Time

Pub.

Title

Presenter

11:30 AM

047

Psychiatric Comorbidities in United States Military Veterans with Movement Disorders in Tampa, Florida

Gender Disparity Between Neurologists in Brazil: Is It Really Decreasing?

Disclosure:
Dr. Dias Veloso has nothing to disclose.

MS Epidemiology, Co-Morbidities, and Modifiable Risk Factors

Start Time

Pub.

Title

Presenter

11:30 AM

054

Clinical and Radiological Correlates of Multiple Sclerosis in patients of Middle Eastern and North African ancestry residing in Ontario, Canada.

Disclosure:
Dr. Seyman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen-Idec. Dr. Seyman has received research support from Novartis.

Heart Brain Connections

Start Time

Pub.

Title

Presenter

11:30 AM

054

Rate of ischemic stroke and intracranial hemorrhage following left ventricular assist device placement: a systematic review

Disclosure:
Dr. Alhaidar has nothing to disclose.

Child Neurology: Leukodystrophies

Start Time

Pub.

Title

Presenter

11:30 AM

054

A Comprehensive and Dynamic Approach for Genetic Testing for Patient with Leukodystrophy Demonstrates a Genetic Etiology in 33% of Cases

Disclosure:
Dr. Zou has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with GeneDx.

History of Neurology

Start Time

Pub.

Title

Presenter

11:30 AM

055

An 8,000-year History of Use and Abuse of Opium and Opioids: How That Matters For A Successful Control Of The Epidemic ?

Disclosure:
Dr. Bandyopadhyay has nothing to disclose.

MS Epidemiology, Co-Morbidities, and Modifiable Risk Factors

Start Time

Pub.

Title

Presenter

11:30 AM

055

The Frequency of Longitudinally Extensive Transverse Myelitis in Multiple Sclerosis in the Era of Glial Biomarkers; A Population-Based Study

Disclosure:
Dr. Asnafi has nothing to disclose.

Heart Brain Connections

Start Time

Pub.

Title

Presenter

11:30 AM

055

Therapeutic Anticoagulation after Ischemic Stroke in Patients with LVADs does not cause Hemorrhagic Conversion: A Single Center Retrospective Study

Disclosure:
Dr. Ruta has nothing to disclose.

Child Neurology: Leukodystrophies

Start Time

Pub.

Title

Presenter

11:30 AM

055

Novel Classifications of Alexander Disease Based on MRI Phenotypes

Disclosure:
Dr. Waldman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with UpToDate, Optum Inc.. Dr. Waldman holds stock and/or stock options in Spark, Thermo Fisher, Pfizer. Dr. Waldman has received research support from Ionis Pharmaceuticals.

History of Neurology

Start Time

Pub.

Title

Presenter

11:30 AM

056

A History of Dihydroergotamine in Migraine

Disclosure:
Dr. Ray has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Impel NeuroPharma.

MS Epidemiology, Co-Morbidities, and Modifiable Risk Factors

Start Time

Pub.

Title

Presenter

11:30 AM

056

Integrative analysis of risk burden, microbiome and metabolome in people at risk for multiple sclerosis

Disclosure:
Dr. Delgado-García has received personal compensation in an editorial capacity for Neurology Resident and Fellow section. Dr. Delgado-García has received research support from Fundacion Carlos Slim.

MS Epidemiology, Co-Morbidities, and Modifiable Risk Factors

Start Time

Pub.

Title

Presenter

11:30 AM

059

Prevalence of Vascular Co-morbidities in patients with Multiple Sclerosis in a Racially Diverse and Low Socioeconomic Status Population

Disclosure:
Dr. Hellerslia has nothing to disclose.

Heart Brain Connections

Start Time

Pub.

Title

Presenter

11:30 AM

059

Neurological outcomes of patients with mycotic aneurysms in infective endocarditis

Disclosure:
Dr. Farbman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. Farbman has received honoraria for advisory board participation from Teva Pharmaceuticals and UCB.

MS Epidemiology, Co-Morbidities, and Modifiable Risk Factors

Start Time

Pub.

Title

Presenter

11:30 AM

062

Multiple Sclerosis Prevalence Rates Within a Healthcare Delivery System in Northern California: A Retrospective, Electronic Health Records-Based Study From 2010 to 2016

Disclosure:
Dr. Romanelli has received research support from Janssen, Regeneron, and Sanofi.

Reimbursement Does Not Cover Inpatient Costs for tPA-Managed Patients As tPA Cost Has Continued to Rise

Disclosure:
Dr. Sila has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with Bristol Myers Squibb Coherex.

MS Epidemiology, Co-Morbidities, and Modifiable Risk Factors

Start Time

Pub.

Title

Presenter

11:30 AM

063

Dietary Intake and the Effect on Disease Progression in People with Multiple Sclerosis

Disclosure:
Dr. Meier-Gerdingh has nothing to disclose.

Heart Brain Connections

Start Time

Pub.

Title

Presenter

11:30 AM

063

Trends of patent foramen ovale (PFO) closure from 2008 to 2014 at National level: US experience

Disclosure:
Dr. Khatri has nothing to disclose.

Child Neurology: Metabolic Disease

Start Time

Pub.

Title

Presenter

11:30 AM

063

Can pathology help in functional interpretation of genetic variants – A case report of Novel variants in NARS2 gene with mitochondrial dysfunction presenting as early infantile epileptic encephalopathy with cardiac and skeletal muscle involvement

Disclosure:
Dr. Heredia has nothing to disclose.

Practice, Policy, and Ethics I

Start Time

Pub.

Title

Presenter

11:30 AM

064

Implementation of an electronic medical record-enhanced dashboard to optimize pre-rounding for residents on the Stroke Neurology service

Collaborative Care in Stroke Centers: Role of Neurologists in Implanting Loop Recorders for Detection of Atrial Fibrillation

Disclosure:
Dr. Herial has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with medtronic.

MS Epidemiology, Co-Morbidities, and Modifiable Risk Factors

Start Time

Pub.

Title

Presenter

11:30 AM

065

The Economic Impact of Multiple Sclerosis: A Preliminary Look at the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) (On behalf of the NARCRMS Health Economics Outcomes Research [HEOR] Advisory Group)

Disclosure:
Dr. Livingston has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with EMD Serono, Biogen.

Disclosure:
Dr. Andrade has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Stoke, Eisai and UCB.. Dr. Andrade has received royalty, license fees, or contractual rights payments from UpToDate.

MS Epidemiology, Co-Morbidities, and Modifiable Risk Factors

Start Time

Pub.

Title

Presenter

11:30 AM

067

The North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) (On behalf of the NARCRMS Site PIs)

Disclosure:
Dr. Rammohan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genzyme, Biogen, EMD Serono, Novartis, TG Therapeutics. Dr. Rammohan has received research support from Genentech, Biogen, EMD Serono, Novartis, Department of Defense.

Disclosure:
Dr. Siva has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Novarti Pharmaceuticals, Teva, Sanofi Genzyme, Bayer, and Roche.

Child Neurology: Epilepsy I

Start Time

Pub.

Title

Presenter

11:30 AM

072

Behavioral alterations associated with the use of levetiracetam in pediatric patients with epilepsy

Disclosure:
Dr. Manterola has nothing to disclose.

Practice, Policy, and Ethics I

Start Time

Pub.

Title

Presenter

11:30 AM

073

Does CMS GMLOS In the Neurological ICU Represent Reality in Academic Medical Centers?

Disclosure:
Dr. Hajighasemi-Ossareh has nothing to disclose.

MS Epidemiology, Co-Morbidities, and Modifiable Risk Factors

Start Time

Pub.

Title

Presenter

11:30 AM

073

Oxysterols and Apolipoproteins in Multiple Sclerosis: A 5-year Follow-up Study

Disclosure:
Dr. Ramanathan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with EMD Serono, Biogen Idec, Pfizer Inc, the National Multiple Sclerosis Society, the Department of Defense, Jog for the Jake Foundation, the National Institutes of Health and National Science Foundation. Dr. Ramanathan has received personal compensation in an editorial capacity for Editor from the American Association of Pharmaceutical Scientists. Dr. Ramanathan has received research support from EMD Serono, Biogen Idec, Pfizer Inc, the National Multiple Sclerosis Society, the Department of Defense, Jog for the Jake Foundation, the National Institutes of Health and National Science Foundation.

Practice, Policy, and Ethics I

Start Time

Pub.

Title

Presenter

11:30 AM

074

The Handoff Experience

Disclosure:
Dr. Streicher has nothing to disclose.

MS Epidemiology, Co-Morbidities, and Modifiable Risk Factors

Start Time

Pub.

Title

Presenter

11:30 AM

074

Generalizability of the Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS-PATHS) Data: Experience from a Single Site

Effects of Guideline on Prevalence of Cerebral Sinus Venous Thrombosis (CSVT) before and after 2011: Call to Action

Disclosure:
Dr. Patel has nothing to disclose.

MS Epidemiology, Co-Morbidities, and Modifiable Risk Factors

Start Time

Pub.

Title

Presenter

11:30 AM

078

Cognitive and clinical predictors of employment status among patients with Multiple Sclerosis in Argentina

Disclosure:
Dr. Vanotti has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen.

Practice, Policy, and Ethics I

Start Time

Pub.

Title

Presenter

11:30 AM

079

Burnout among practicing neurologists in Massachusetts

Disclosure:
Dr. Wu has nothing to disclose.

MS Epidemiology, Co-Morbidities, and Modifiable Risk Factors

Start Time

Pub.

Title

Presenter

11:30 AM

079

Worsening of MS Associated With Relapse Contributes to Disability Over the First 15 years

Disclosure:
Dr. Diehl has nothing to disclose.

Practice, Policy, and Ethics I

Start Time

Pub.

Title

Presenter

11:30 AM

080

Impact of Transthoracic Echocardiogram on Length of Stay and Hospital Charges in Ischemic Stroke and Transient Ischemic Attack Patients in United States: Analysis of Nationwide Inpatient Sample 2006-2014

Disclosure:
Dr. Nguyen has nothing to disclose.

MS Epidemiology, Co-Morbidities, and Modifiable Risk Factors

Start Time

Pub.

Title

Presenter

11:30 AM

080

Personality traits and perception of health-related quality of life in people with multiple sclerosis: An analysis of the NEO-FFI-3 and MSIS-29 questionnaires

Disclosure:
Dr. Cuello has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen. Dr. Cuello has received research support from Biogen.

11:30 AM

093

The use natalizumab in multiple sclerosis patients during pregnancy is safe and prevents disease reactivation

Disclosure:
Dr. Alroughani has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer, Biogen, Biologix, Merck, Novartis, Roche and Sanofi. Dr. Alroughani has received research support from Biogen, Merck, Novartis, Roche and Sanofi.

11:30 AM

094

Anti CD20 Therapies and Pregnancy in Neuroimmunological Disorders – A Case Series from Germany

Pregnancy Outcomes From an International Registry of Patients Treated With Delayed-release Dimethyl Fumarate

Disclosure:
Dr. Everage has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen. Dr. Everage holds stock and/or stock options in Biogen, which sponsored research in which Dr. Everage was involved as an investigator. Dr. Everage holds stock and/or stock options in Biogen.

11:30 AM

096

Pregnancy outcomes in patients with multiple sclerosis and exposure to branded glatiramer acetate

Disclosure:
Dr. Qassem has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Teva.

11:30 AM

097

Minimal concentrations of rituximab in the breastmilk of women treated for multiple sclerosis